We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 108

A Stay of Litigation Pending IPR Does Not Provide a Basis For Extending 30-Stay of FDA ANDA Approval
  • Locke Lord LLP
  • USA
  • January 12 2016

On December 11, 2015, the United States District Court for the Southern District of Indiana granted a motion to stay a Hatch-Waxman litigation

Indiana’s Right to Try Law: catalyst for expanded access to experimental drugs for terminally ill patients
  • Taft Stettinius & Hollister LLP
  • USA
  • March 30 2015

Indiana Governor Mike Pence signed into law Indiana’s new Right to Try legislation on March 24, but this law (and similar legislation proposed and

Indiana’s “government compliance” presumption against defect and negligence
  • Dechert LLP
  • USA
  • May 13 2013

The Indiana Court of Appeals recently issued an opinion applying the section of Indiana's Product Liability Act (IPLA) that, under certain

Fresh squeezed or made from concentrate?
  • Shook Hardy & Bacon LLP
  • USA
  • June 17 2011

Alabama and Indiana residents have filed a putative class action alleging violation of state consumer protection laws by a company that promotes its orange juice as “not from concentrate juice” and “100 pure Florida squeezed,” when it allegedly “contains orange juice concentrate and water.”

District court rules failure-to-warn claims for prescription drug labeling are not preempted
  • Faegre Baker Daniels LLP
  • USA
  • July 25 2008

The U.S. District Court for the Southern District of Indiana recently issued a ruling that has important repercussions for pharmaceutical manufacturers.

Ilunga L. Kalala
  • Kelley Drye & Warren LLP